OMDA Omada Health, Inc.

BULLISH Impact: 7/10 8-K
Horizon weeks Filed May 7, 2026 Processed 1mo ago SEC 0001628280-26-032063
8-K Item 2.02: Earnings release
Latest settled — T+20d
OMDA ▲ +20.99% at T+20d
LONG call ✓ call won +20.99% · α vs SPY +20.96% · entry $14.82 → $17.93
Next anchor: T+60d in 8w
Last close $17.88 (close Jun 8) · +20.65% from $14.82 entry
Entry anchored
May 7, 03:59 PM ET
via Databento tick
T+1d
-0.88%
call -0.88% · α -1.11%
$14.69
settled 5w ago
T+5d
+11.88%
call +11.88% · α +10.41%
$16.58
settled 27d ago
T+20d
+20.99%
call +20.99% · α +20.96%
$17.93
settled 5d ago
T+60d
call — · α —
in 8w

Price Chart

Loading chart...

Executive Summary

Omada Health reports Q1 2026 revenue of $78M (+42% YoY), beating consensus of $74.1M, but GAAP EPS of -$0.05 missed the -$0.04 estimate. The company raised full-year revenue guidance to $322-$330M and adjusted EBITDA guidance to $14-$20M, both above prior outlook. Strong member growth (1.02M, +51% YoY) and expanded PBM partnerships support the bullish outlook.

Key Financial Metrics

Guidance
$322M-$330M
raised
Free Cash Flow
-$13.4M
Gross Margin
62.4%

Actionable Insight

The raised guidance and accelerating member growth signal improving fundamentals. However, EPS still negative and cash burn continues; watch for sustained operating leverage in upcoming quarters. The stock may react positively to the revenue beat and guidance raise, but historical T+20 performance on bullish calls has been weak, suggesting potential profit-taking after initial pop.

Key Facts

  • Revenue $78.048M, up 42% YoY, beat consensus of $74.1M
  • GAAP net loss narrowed to $2.97M from $9.45M YoY; EPS -$0.05 vs -$1.15
  • Total members surpassed 1 million, up 51% YoY
  • FY2026 revenue guidance raised to $322-$330M (prior $312-$322M)
  • FY2026 adjusted EBITDA guidance raised to $14-$20M (prior $7-$15M)
  • New partnerships with Optum Rx and Lilly Employer Connect program
  • Gross margin improved to 62% from 58% YoY
  • Adjusted EBITDA turned positive: $1M vs -$4M YoY

Financial Impact

Revenue beat of $3.95M (5.3%) and guidance raise of ~$9M at midpoint

revenueepsguidancemembersebitda

Risk Factors

  • EPS miss vs consensus despite revenue beat
  • Negative free cash flow of -$13.4M in Q1
  • High dependency on GLP-1 program adoption and PBM relationships
  • History of weak T+20 stock performance after bullish earnings reports

Market Snapshot

Exchange
Nasdaq
Sector
Services-Health Services
Analyst Consensus
83% bullish (18 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-032063
Document: omda-20260507.htm0001628280-26-032063
Document: 0001628280-26-032063-index-headers.html0001628280-26-032063
Document: 0001628280-26-032063-index.html0001628280-26-032063
Document: 0001628280-26-032063.txt0001628280-26-032063
8-K Data (Synthetic)0001628280-26-032063
4 reports for OMDA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for OMDA — sortable, filterable
Type Now
May 7, 2026
4w ago
8-K
BULLISH ★ 7/10
$14.82 $17.93▲ +20.99%▲ +20.96%$17.88 (+20.65%)
Apr 16, 2026
7w ago
Press Release
NEUTRAL ★ 3/10
$13.37 $16.04▲ +19.97%▲ +14.15%$17.88 (+33.73%)
Mar 5, 2026
13w ago
8-K
BULLISH ★ 8/10
$14.05 $12.58▼ −10.46%▼ −8.42%$17.88 (+27.26%)
Mar 5, 2026
13w ago
Press Release
BULLISH ★ 8/10
$14.05 $12.58▼ −10.46%▼ −8.42%$17.88 (+27.26%)
Showing 4 of 4

US Market Status

Market Closed — Opens in 6h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access